不同二线治疗方案对转移性尿路上皮癌的疗效

Q4 Medicine Open Urology and Nephrology Journal Pub Date : 2017-12-18 DOI:10.2174/1874303X01710010052

Lukas Barwitz, A. Berger, Stefanie Zschaebitz, M. Jenzer, C. Nientiedt, S. Duensing, D. Jäger, D. Teber, M. Hohenfellner, C. Grüllich

{"title":"不同二线治疗方案对转移性尿路上皮癌的疗效","authors":"Lukas Barwitz, A. Berger, Stefanie Zschaebitz, M. Jenzer, C. Nientiedt, S. Duensing, D. Jäger, D. Teber, M. Hohenfellner, C. Grüllich","doi":"10.2174/1874303X01710010052","DOIUrl":null,"url":null,"abstract":"Results: Median overall survival (OS) from first line therapy over all lines was 28,0 months. Median OS from second line was 14,7 months (95% CI, 11,4-18,0). No significant differences between regimens could be detected. OS of patients with lymphonodal only involvement (n=16, 22,5%) was 35.5 months (95% CI 0.0-73.9), OS with visceral metastases excluding liver was 14.7 months (95% CI 9.8-19.6) .and OS with any liver involvement was 9.4 months (95% CI 0.0-20.9).","PeriodicalId":38952,"journal":{"name":"Open Urology and Nephrology Journal","volume":"10 1","pages":"52-58"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Efficacy of Different Second-line Therapy Regimens in Metastatic Urothelial Carcinoma\",\"authors\":\"Lukas Barwitz, A. Berger, Stefanie Zschaebitz, M. Jenzer, C. Nientiedt, S. Duensing, D. Jäger, D. Teber, M. Hohenfellner, C. Grüllich\",\"doi\":\"10.2174/1874303X01710010052\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Results: Median overall survival (OS) from first line therapy over all lines was 28,0 months. Median OS from second line was 14,7 months (95% CI, 11,4-18,0). No significant differences between regimens could be detected. OS of patients with lymphonodal only involvement (n=16, 22,5%) was 35.5 months (95% CI 0.0-73.9), OS with visceral metastases excluding liver was 14.7 months (95% CI 9.8-19.6) .and OS with any liver involvement was 9.4 months (95% CI 0.0-20.9).\",\"PeriodicalId\":38952,\"journal\":{\"name\":\"Open Urology and Nephrology Journal\",\"volume\":\"10 1\",\"pages\":\"52-58\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-12-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Urology and Nephrology Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1874303X01710010052\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Urology and Nephrology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874303X01710010052","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

摘要

结果:一线治疗的中位总生存期(OS)为280个月。二线的中位OS为14.7个月(95% CI, 11,4-18,0)。两种治疗方案之间未发现显著差异。仅淋巴结受累(n=16、22、5%)患者的生存期为35.5个月(95% CI 0-73.9)，不包括肝脏的内脏转移的生存期为14.7个月(95% CI 9.8-19.6)，任何肝脏受累的生存期为9.4个月(95% CI 0-20.9)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Efficacy of Different Second-line Therapy Regimens in Metastatic Urothelial Carcinoma

Results: Median overall survival (OS) from first line therapy over all lines was 28,0 months. Median OS from second line was 14,7 months (95% CI, 11,4-18,0). No significant differences between regimens could be detected. OS of patients with lymphonodal only involvement (n=16, 22,5%) was 35.5 months (95% CI 0.0-73.9), OS with visceral metastases excluding liver was 14.7 months (95% CI 9.8-19.6) .and OS with any liver involvement was 9.4 months (95% CI 0.0-20.9).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Open Urology and Nephrology Journal Medicine-Urology

CiteScore

0.30

自引率

0.00%

发文量